In a multicenter, Simon two-stage phase 2 trial involving 30 patients with HPV-negative, cetuximab-resistant R/M HNSCC, cetuximab was combined with an anti-ErbB3 monoclonal antibody CDX-3379. Here, ERBB3 is linked to head and neck squamous cell carcinoma.